Actinium Pharmaceuticals Overview
Valuation check: ATNM's ROE is 37.32%, above the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow37.32%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Actinium Pharmaceuticals (ATNM) currently reports a ROE of 37.32%. That is above the Healthcare sector average of 20.77%. Use the charts on this page to explore Actinium Pharmaceuticals's ROE history and peer comparisons.
Actinium Pharmaceuticals's ROE of 37.32% is higher than the Healthcare sector average of 20.77%. That is roughly 79.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Actinium Pharmaceuticals's current 37.32% should be judged against Healthcare norms (sector average: 20.77%) and against ATNM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 37.32%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Actinium Pharmaceuticals, and consider following ATNM for alerts when major investors trade the stock.
Actinium Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 37.32% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATNM with unrelated industries.
